Novartis Announces FDA Approval For Arcapta To Treat COPD Symptoms
Links shared publicly online about this topic.
- 177total visits
Novartis Announces FDA Approval For Arcapta To Treat COPD Symptoms
Novartis AG (NVS), Friday announced that the US Food and Drug Administration has approved once-daily Arcapta Neohaler (indacaterol inhalation powder) 75 mcg for the long-term maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease.
View full resource at rttnews.com
Tags: COPD, Diet and Nutrition, Drug, FDA, Novartis, Pulmonology
Most Recently Shared on July 2, 2011 at 2:30 am By:
Novartis Announces FDA Approval For Arcapta To Treat COPD Symptoms, once a day bronchodilator - http://goo.gl/cd9hS
Advertisement
